Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Blue Owl Capital Holdings LP

August 12, 2026 4:32 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The reported securities represent 511,177 Common Shares issuable upon exercise of warrants to each acquire one Common Share ("Warrants"). The reported percentage is calculated based on 66,989,466 Common Shares outstanding as of June 9, 2026, as reported on the Issuer's 10-Q filed with the Securities and Exchange Commission on June 15, 2026, and as increased by the 511,177 Common Shares issuable upon exercise of the Warrants.


SCHEDULE 13G



Blue Owl Capital Holdings LP
Signature:/s/ Karen Hager
Name/Title:Karen Hager / Chief Compliance Officer
Date:08/12/2026

Categories

SEC Filings